We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Epidemiological EMESIS-Registry (EMESIS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00911222
First Posted: June 1, 2009
Last Update Posted: December 24, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Arbeitsgemeinschaft fur Internistische Onkologie
ASORS
Arbeitskreis Klinische Studien
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
iOMEDICO AG
  Purpose
The purpose of this registry is to record information on reality of anti-emetic therapies of cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic therapies dependent on the rate "complete and major control" of nausea and emesis in moderately and highly emetogenic chemotherapies, consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.

Condition Intervention
Antiemetic Therapy Other: non-interventional

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Epidemiologic Registry for the Description of Antiemetic Strategies Under Real-life Conditions.

Resource links provided by NLM:


Further study details as provided by iOMEDICO AG:

Primary Outcome Measures:
  • Efficacy of anti-emetic therapies dependent on the rate "complete and major control" of nausea and emesis in moderately and highly emetogenic chemotherapy regimens. [ Time Frame: 4 chemotherapy applications per patient ]

Enrollment: 1035
Study Start Date: October 2008
Study Completion Date: August 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
antiemetic treatment
epidemiological registry
Other: non-interventional
non-interventional

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Practitioners specialized in oncology, hematology and/or gynaecology
Criteria

Inclusion Criteria:

  • Moderately or highly emetogenic chemotherapy consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.
  • start with the 1st cycle of the regimen (chemo naive patients). Inclusion of pretreated patients is also possible, if the last treatment cycle of a previous chemotherapy was given >= 24 months ago.
  • Compliance with registry procedures
  • Age >= 18 years
  • WHO Performance Status of 0 or 1 (Karnofsky-Index >= 70%)
  • Life expectancy of at least 12 weeks
  • Signed and dated informed consent before the start of the registry

Exclusion Criteria:

  • Mentally incapable or incompliant patients
  • Last chemotherapy <= 24 months (if pretreated)
  • Known hypersensitivity to antiemetic medication
  • unability of the patient to be treated with oral medication
  • pregnancy or lactation period
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00911222


Locations
Germany
iOMEDICO AG
Freiburg, Baden-Württemberg, Germany, 79108
Sponsors and Collaborators
iOMEDICO AG
Arbeitsgemeinschaft fur Internistische Onkologie
ASORS
Arbeitskreis Klinische Studien
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Jan Schröder, Dr. med. / MD Praxis für Hämatologie und Onkologie
  More Information

Publications:
Responsible Party: iOMEDICO AG
ClinicalTrials.gov Identifier: NCT00911222     History of Changes
Other Study ID Numbers: IOM-143
First Submitted: May 28, 2009
First Posted: June 1, 2009
Last Update Posted: December 24, 2014
Last Verified: December 2014

Keywords provided by iOMEDICO AG:
antiemetic therapy
emesis
vomiting
nausea
moderately and highly emetogenic chemotherapy
cisplatin
carboplatin
oxaliplatin
anthracycline
cyclophosphamid

Additional relevant MeSH terms:
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents